Table 4.
Key clinical trials of immunotherapy combined with anti-angiogenic therapy.
| Study | Indication | Phase | Treatment (n) | Efficacy endpoints | Grade 3/4 AEs | Reference | ||
|---|---|---|---|---|---|---|---|---|
| RR | PFS | OS | ||||||
| IMpower150 (NCT02366143) | NSCLC | 3 | Atezolizumab + bevacizumab + carboplatin + paclitaxel (394) | 56.4% | 10.2 m | Not estimable | 57% | [261] |
| Atezolizumab + carboplatin + paclitaxel (399) | 40.6% | 6.9 m | 18.7 m | 43% | ||||
| IMmotion150 (NCT01984242) | RCC | 2 | Atezolizumab + bevacizumab (101) | 32% | 11.7 m | / | 63% | [128] |
| Atezolizumab (103) | 25% | 6.1 m | / | 40% | ||||
| Sunitinib (101) | 29% | 8.4 m | / | 69% | ||||
| IMmotion151 (NCT02420821) | RCC | 3 | Atezolizumab + bevacizumab (454) | 37% | 11.2 m | 33.6 m | 40% | [262] |
| Sunitinib (461) | 33% | 8.4 m | 34.9 m | 54% | ||||
| IMbrave150 (NCT03434379) | HCC | 3 | Atezolizumab + bevacizumab (336) | 27.3% | 6.8 m | 19.2 m | 56.5% | [126, 263] |
| Sorafenib (165) | 11.9% | 4.3 m | 13.4 m | 55.1% | ||||
| KEYNOTE-146 (NCT02501096) | Endometrial cancer | 1b/2 | Lenvatinib+ pembrolizumab (108) | 38.9% | 21.2 m | 7.4 m | 66.9% | [264] |
| KEYNOTE-775 (NCT03517449) | Endometrial cancer | 3 | Pembrolizumab + Lenvatinib (413) | 30% | 6.6 m | 17.4 m | / | [265] |
| Chemotherapy (413) | 15% | 3.8 m | 12.0 m | / | ||||
| KEYNOTE-426 (NCT02853331) | RCC | 3 | Pembrolizumab + axitinib (432) | 59.3% | 15.1 m | Not reached | / | [124] |
| Sunitinib (429) | 35.7% | 11.1 m | 35.7 m | / | ||||
| JAVELIN Renal 101 (NCT02684006) | RCC | 3 | Avelumab + axitinib (442) | 52.5% | 13.8 | / | 71.2% | [129, 130, 266] |
| Sunitinib (444) | 27.3% | 8.4 | / | 71.5% | ||||
| EPOC1706 (NCT03609359) | Gastric cancer | 2 | Lenvatinib + pembrolizumab (29) | OR 20/29 | 7.1 m | / | 48% | [267] |
| BO17705E (NCT00738530) | RCC | 3 | Bevacizumab + interferon alfa (325) | 31% | 10.2 m | / | 29% | [268] |
| Interferon alfa (316) | 13% | 5.4 m | 19.8 m | 16% | ||||
| ORIENT-32 (NCT03794440) | HCC | 2/3 | Sintilimab + bevacizumab biosimilar (380) | 21% | 4.6 m | Not reached | / | [269] |
| Sorafenib (191) | 4% | 2.8 m | 10.4 m | / | ||||
| KEYNOTE-581 (NCT02811861) | RCC | 3 | Lenvatinib + pembrolizumab (355) | 71.0% | 23.9 m | 2-year OS rate 79.2% vs. 66.1% vs. 70.4% | 82.4% | [270] |
| Lenvatinib + everolimus (357) | 53.5% | 14.7 m | 83.1% | |||||
| Sunitinib (357) | 36.1% | 9.2 m | 71.8% | |||||
| NCT03603756 | ESCC | 2 | Camrelizumab + apatinib + chemotherapy (30) | 80.0% | 6.85 m | 19.43 m | 90.0% | [271] |